Skip to main content

Advertisement

Table 3 Demographic, clinical, and laboratory characteristics at renal biopsy and treatment

From: Association of high body mass index with development of interstitial fibrosis in patients with IgA nephropathy

Total Model 1 Model 2 Model 3
< 18.5 18.5–25 P value 18.5–25 25–28 P value 18.5–25 ≥28 P value
No. of patients 295 37 37   48 48   12 12  
Follow-up time
(months)
45.4 ± 26.6 36.3 ± 24.0 43.3 ± 23.6 0.158 41.5 ± 23.1 43.9 ± 34.3 0.682 40.4 ± 28.2 41.5 ± 21.6 0.810
eGFR
(ml/min per 1.73 m2)
88.82 ± 31.57 103.84 ± 34.25 99.83 ± 34.91 0.406 83.99 ± 33.18 83.75 ± 29.88 0.809 76.32 ± 41.11 87.41 ± 30.83 0.722
Proteinuria (g/24 h) 1.60 ± 8.78 0.60 ± 0.46 0.74 ± 0.69 0.567 0.84 ± 0.82 1.01 ± 0.85 0.105 1.22 ± 0.99 1.39 ± 1.43 0.786
Treatment           
P 17 2 2 1 4 2 0.677 0 0 1
P + CTX 1 1 0 1 0 0 1 0 0 1
P + LEF 5 1 1 1 0 1 1 0 0 1
ACEI/ARB 70 10 8 0.787 8 14 0.224 3 2 1
P + ACEI/ARB 81 6 12 0.173 14 11 0.642 4 5 1
  1. Abbreviations: P prednisone; CTX cytoxan; LEF leflunomide; ACEI angiotensin-converting enzyme inhibitors; ARB angiotensin receptor antagonist
  2. Model 1, 2 and 3 were performed by propensity-score matching. The matching covariates were age, sex, eGFR and proteinuria. The control group were patients with normal weight (18.5 ≤ BMI<25 kg/m2), and the matching group were patients with low-weight (BMI<18.5 kg/m2), overweight (25 ≤ BMI<28 kg/m2) and obese (BMI ≥ 28 kg/m2)